Petrus Trust Company LTA Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Petrus Trust Company LTA acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 52,900 shares of the medical research company’s stock, valued at approximately $26,522,000. Thermo Fisher Scientific makes up 2.5% of Petrus Trust Company LTA’s investment portfolio, making the stock its 15th biggest position.

Several other large investors have also recently bought and sold shares of the business. High Note Wealth LLC raised its stake in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Kilter Group LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Birchwood Financial Partners Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Legacy Wealth Managment LLC ID increased its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $634.48 on Thursday. The business’s 50 day simple moving average is $552.22 and its 200-day simple moving average is $510.70. The firm has a market capitalization of $234.60 billion, a price-to-earnings ratio of 34.13, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Analyst Upgrades and Downgrades

Several analysts recently commented on TMO shares. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Morgan Stanley raised their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target for the company. Piper Sandler boosted their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Finally, Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock valued at $44,122,820 in the last quarter. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.